ReviewMolecular neurobiology2017
Relationship Between Obesity, Alzheimer's Disease, and Parkinson's Disease: an Astrocentric View.
Review in Molecular neurobiology, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 43 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
43 citing papers in PubMed.
- Effect of Amla Extract on Body Mass Index, Waist Circumference, Total Body Fat, Visceral Fat, Skeletal Muscle Mass, Body Age, and Related Parameters: A Randomized, Open-Label Clinical Study in Obese Participants.Complementary medicine research · 2025Trial
- Bariatric surgery and risk of dementia and Parkinson's disease in patients with obesity.International journal of obesity (2005) · 2026Article
- The Influence of Metabolic Dysfunction-Associated Steatotic Liver Disease and Body Mass Index on the Incidence of Alzheimer Disease: A Nationwide Cohort Study.Gut and liver · 2026Article
- Article
- Association Between Relative Fat Mass and Parkinson's Disease in American Adults: A Large Cross-Sectional Study From NHANES.Parkinson's disease · 2026Article
- Body mass index, metabolically abnormal status, and incident Parkinson's disease: Data from the UK Biobank.Journal of Parkinson's disease · 2025Article
- Targeting Metabolic Dysfunction in Parkinson's Disease: The Role of GLP-1 Agonists in Body Weight Regulation and Neuroprotection.Current diabetes reports · 2025Review
- Inter-Organ Crosstalk in Neurodegenerative Disease.Life (Basel, Switzerland) · 2025Review
- Mechanisms Linking Obesity, Insulin Resistance, and Alzheimer's Disease: Effects of Polyphenols and Omega-3 Polyunsaturated Fatty Acids.Nutrients · 2025Review
- Value of blood biomarkers in the diagnosis of Parkinson's disease: a case-control study from Xinjiang.BMC neurology · 2025Article
- Association between life's essential 8 and Parkinson's disease: a case-control study.BMC public health · 2025Article
- Associations between eight anthropometric indices and Parkinson's disease: a nationwide population-based study.Frontiers in nutrition · 2025Article
- Modulation of Urea Transport Attenuates TLR2-Mediated Microglial Activation and Upregulates Microglial Metabolism In Vitro.Metabolites · 2024Article
- Childhood obesity and risk of Alzheimer's disease: a Mendelian randomization study.Archives of public health = Archives belges de sante publique · 2024Article
- Association between a body shape index and Parkinson's disease: A large cross-sectional study from NHANES.Heliyon · 2024Article
- Mendelian randomization analysis of the causal relationship between trimethylamine N-oxide and its precursors and Parkinson's disease.Archives of medical science : AMS · 2024Article
- Abnormalities in Copper Status Associated with an Elevated Risk of Parkinson's Phenotype Development.Antioxidants (Basel, Switzerland) · 2023Review
- Metabolic Profile of Alzheimer's Disease: Is 10-Hydroxy-2-decenoic Acid a Pertinent Metabolic Adjuster?Metabolites · 2023Review
- Blood Biomarkers in Patients with Parkinson's Disease: A Review in Context of Anesthetic Care.Diagnostics (Basel, Switzerland) · 2023Review
- The complex relationship between obesity and neurodegenerative diseases: an updated review.Frontiers in cellular neuroscience · 2023Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Obesity is considered one of the greatest risk to human health and is associated with several factors including genetic components, diet, and physical inactivity. Recently, the relationship between obesity and numerous progressive and aging-related neurodegenerative diseases such as Parkinson's disease (PD) and Alzheimer's disease (AD) have been observed. Thus, the involvement of the most abundant and heterogeneous group of glial cells in neurodegenerative diseases, the astrocytes, is caused by a combination of the failure on their normal homeostatic functions and the increase of toxic metabolites upon pathological event. Upon brain damage, molecular signals induce astrocyte activation and migration to the site of injury, entering in a highly active state, with the aim to contribute to ameliorating or worsening the pathology. In this regard, the aim of this review is to elucidate the relationship between obesity, Alzheimer's disease, and Parkinson's disease and highlight the role of astrocytes in these pathologies.
Indexed as
Identifiers
27796748What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.